Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Colorcon
Dow
Boehringer Ingelheim
Moodys

Last Updated: August 15, 2022

Investigational Drug Information for Amylamine


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Amylamine?

Amylamine is an investigational drug.

There have been 20 clinical trials for Amylamine. The most recent clinical trial was a Phase 3 trial, which was initiated on June 13th 2019.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Yale University, CoMentis, and Targacept Inc.

There are two hundred and eighty-four US patents protecting this investigational drug and twenty-two international patents.

Recent Clinical Trials for Amylamine
TitleSponsorPhase
Cholinergic Mechanisms of Attention in AgingVanderbilt University Medical CenterEarly Phase 1
Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar HyperhidrosisAtacama TherapeuticsPhase 2
Mecamylamine for Autonomic Dysreflexia ProphylaxisWayne State UniversityPhase 4

See all Amylamine clinical trials

Clinical Trial Summary for Amylamine

Top disease conditions for Amylamine
Top clinical trial sponsors for Amylamine

See all Amylamine clinical trials

US Patents for Amylamine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Amylamine See Plans and Pricing Template-fixed peptidomimetics POLYPHOR LTD. (Allschwil, CH) See Plans and Pricing
Amylamine See Plans and Pricing Cyclic amine azaheterocyclic carboxamides Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
Amylamine See Plans and Pricing Glycan conjugates and use thereof ACADEMIA SINICA (Taipei, TW) See Plans and Pricing
Amylamine See Plans and Pricing Beta-hairpin peptidomimetics as selective elastase inhibitors POLYPHOR AG (Allschwil, CH) See Plans and Pricing
Amylamine See Plans and Pricing Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same NEW YORK UNIVERSITY (New York, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Amylamine

Drugname Country Document Number Estimated Expiration Related US Patent
Amylamine Argentina AR054191 2025-05-13 See Plans and Pricing
Amylamine Australia AU2006244851 2025-05-13 See Plans and Pricing
Amylamine Australia AU2010201952 2025-05-13 See Plans and Pricing
Amylamine Brazil BRPI0610279 2025-05-13 See Plans and Pricing
Amylamine Canada CA2608184 2025-05-13 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Colorcon
Dow
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.